Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Does Genotype Affect the Efficacy of PCSK9 Inhibitors in the Treatment of Familial Hypercholesterolemia?

Cardiovascular drugs and therapy - 1 Apr 2025

Tandirerung Fistra Janrio

Abstract excerpt

PURPOSE OF REVIEW: This review discusses whether patients' genotype affects the efficacy of PCSK9 inhibitors in treating familial hypercholesterolemia and how this might influence clinical management. RECENT FINDINGS: Currently, available evidence consistently demonstrates and is in good agreement that, in general, the LDL-C-lowering effect of PCSK9 inhibitors is similar across genotypes, except for compound...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticholesteremic Agents
Share to Biomarkers
Share to Cholesterol, LDL

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Heterozygote

Share to Hyperlipoproteinemia Type II

Share to Proprotein Convertase 9

Share to Serine Proteinase Inhibitors

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 37610687
DOI: 10.1007/s10557-023-07505-5
PMCID: PMC11954701

Genes

PCSK9
FH

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Does Genotype Affect the Efficacy of PCSK9 Inhibitors in the Treatment of Familial Hypercholesterolemia?PMID 37610687Read ↗

[The relationship between genotype of familial hypercholesterolemia and the efficacy of PCSK9 inhibitors].Semantic proximity Read ↗

PCSK9 Variants in Familial Hypercholesterolemia: A Comprehensive SynopsisSemantic proximity Read ↗

Association between causative mutations and response to PCSK9 inhibitor therapy in subjects with familial hypercholesterolemia: A single center real-world study.Semantic proximity Read ↗

Phenotype vs. genotype in severe familial hypercholesterolemia: what matters most for the clinician?Semantic proximity Read ↗

The Clinical Importance of Differentiating Monogenic Familial Hypercholesterolemia from Polygenic HypercholesterolemiaSemantic proximity Read ↗

Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia.Semantic proximity Read ↗

PCSK9 and Lipid Metabolism: Genetic Variants, Current Therapies, and Cardiovascular Outcomes.Semantic proximity Read ↗

Are Genetic Tests for Atherosclerosis Ready for Routine Clinical Use?Semantic proximity Read ↗

[PERSONALIZED APPROACH TO LIPID-LOWERING THERAPY].Semantic proximity Read ↗

LDL-cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid-lowering therapy.Semantic proximity Read ↗

The contribution of PCSK9 levels to the phenotypic severity of familial hypercholesterolemia is independent of LDL receptor genotype.Semantic proximity Read ↗

Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.